Therapeutic Effects of Lenalidomide on Hemorrhagic Intestinal Myeloma-associated AL Amyloidosis
A 74-year-old woman with refractory IgG-κ multiple myeloma developed massive melena caused by hemorrhagic submucosal tumors in the duodenum and middle jejunum. A biopsy revealed the tumor to be marked AL amyloid deposition. Treatment with bortezomib did not improve the melena or the underlying disea...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2013, Vol.52(10), pp.1101-1105 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1105 |
|---|---|
| container_issue | 10 |
| container_start_page | 1101 |
| container_title | Internal Medicine |
| container_volume | 52 |
| creator | Nagano, Seiji Mori, Minako Kato, Aiko Ono, Yuichiro Aoki, Kazunari Arima, Hiroshi Takiuchi, Yoko Tabata, Sumie Yanagita, Soshi Matsushita, Akiko Ishikawa, Takayuki Imai, Hiroyuki Takahashi, Takayuki |
| description | A 74-year-old woman with refractory IgG-κ multiple myeloma developed massive melena caused by hemorrhagic submucosal tumors in the duodenum and middle jejunum. A biopsy revealed the tumor to be marked AL amyloid deposition. Treatment with bortezomib did not improve the melena or the underlying disease. The patient also developed multiple amyloidomas in the bilateral femoral heads, which caused a fracture in the left femoral head. Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma. This case shows that successful treatment of multiple myeloma leads to marked improvement of accompanying AL amyloidosis. |
| doi_str_mv | 10.2169/internalmedicine.52.8615 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1534811543</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1534811543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c617t-456645548ac2a51a27aa8aa3a39574f5da152bfd732a11e44c06b7e7d5766eaf3</originalsourceid><addsrcrecordid>eNqFkUtPwzAQhC0EglL4C8hHLinxOzlWiJdUxAXO1tbZUKMkLnZ66L_HqKUHhMRlffA3M6sdQigrZ5zp-sYPI8YBuh4b7_yAM8VnlWbqiEyYkHVhuFDHZFLWrCp4HmfkPKWPshSVqfkpOeNCG63qakLs6wojrHEzekfv2hbdmGho6QKzvW9C7xukYaCP2IcYV_CesaecnkafAfq8xS70UEBKwXkYsaHzBZ332y5kcfLpgpy00CW83L9T8nZ_93r7WCxeHp5u54vCaWbGQiqtpVKyAsdBMeAGoAIQIGplZKsaYIov28YIDoyhlK7US4OmUUZrhFZMyfXOdx3D5yavZ3ufHHYdDBg2yTIlZMWYkuJ_VChRiprlI05JtUNdDClFbO06-h7i1rLSfjdhfzdhFbffTWTp1T5ls8yfB-HP6TPwsgM-0gjveAAg5io6_NM5p-a5jziQbgXR4iC-AI-Yp8k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1353039172</pqid></control><display><type>article</type><title>Therapeutic Effects of Lenalidomide on Hemorrhagic Intestinal Myeloma-associated AL Amyloidosis</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><creator>Nagano, Seiji ; Mori, Minako ; Kato, Aiko ; Ono, Yuichiro ; Aoki, Kazunari ; Arima, Hiroshi ; Takiuchi, Yoko ; Tabata, Sumie ; Yanagita, Soshi ; Matsushita, Akiko ; Ishikawa, Takayuki ; Imai, Hiroyuki ; Takahashi, Takayuki</creator><creatorcontrib>Nagano, Seiji ; Mori, Minako ; Kato, Aiko ; Ono, Yuichiro ; Aoki, Kazunari ; Arima, Hiroshi ; Takiuchi, Yoko ; Tabata, Sumie ; Yanagita, Soshi ; Matsushita, Akiko ; Ishikawa, Takayuki ; Imai, Hiroyuki ; Takahashi, Takayuki</creatorcontrib><description>A 74-year-old woman with refractory IgG-κ multiple myeloma developed massive melena caused by hemorrhagic submucosal tumors in the duodenum and middle jejunum. A biopsy revealed the tumor to be marked AL amyloid deposition. Treatment with bortezomib did not improve the melena or the underlying disease. The patient also developed multiple amyloidomas in the bilateral femoral heads, which caused a fracture in the left femoral head. Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma. This case shows that successful treatment of multiple myeloma leads to marked improvement of accompanying AL amyloidosis.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.52.8615</identifier><identifier>PMID: 23676598</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject><![CDATA[Aged ; AL amyloidosis ; Amyloid - metabolism ; Amyloidosis - drug therapy ; Amyloidosis - etiology ; Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Blood Transfusion ; bone amyloidosis ; Bone Diseases - drug therapy ; Bone Diseases - etiology ; Boronic Acids - administration & dosage ; Bortezomib ; Carpal Tunnel Syndrome - etiology ; Dexamethasone - administration & dosage ; Disease Progression ; Doxorubicin - administration & dosage ; Duodenal Diseases - drug therapy ; Duodenal Diseases - etiology ; Female ; Femur Head - pathology ; Fractures, Spontaneous - etiology ; Gastrointestinal Hemorrhage - etiology ; Gastrointestinal Hemorrhage - therapy ; Hip Fractures - etiology ; Humans ; intestinal amyloidosis ; Jejunal Diseases - drug therapy ; Jejunal Diseases - etiology ; Lenalidomide ; Melphalan - administration & dosage ; multiple myeloma ; Multiple Myeloma - complications ; Multiple Myeloma - drug therapy ; Osteolysis - etiology ; Prednisolone - administration & dosage ; Pyrazines - administration & dosage ; Thalidomide - administration & dosage ; Thalidomide - analogs & derivatives ; Thalidomide - therapeutic use ; Vincristine - administration & dosage]]></subject><ispartof>Internal Medicine, 2013, Vol.52(10), pp.1101-1105</ispartof><rights>2013 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c617t-456645548ac2a51a27aa8aa3a39574f5da152bfd732a11e44c06b7e7d5766eaf3</citedby><cites>FETCH-LOGICAL-c617t-456645548ac2a51a27aa8aa3a39574f5da152bfd732a11e44c06b7e7d5766eaf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23676598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nagano, Seiji</creatorcontrib><creatorcontrib>Mori, Minako</creatorcontrib><creatorcontrib>Kato, Aiko</creatorcontrib><creatorcontrib>Ono, Yuichiro</creatorcontrib><creatorcontrib>Aoki, Kazunari</creatorcontrib><creatorcontrib>Arima, Hiroshi</creatorcontrib><creatorcontrib>Takiuchi, Yoko</creatorcontrib><creatorcontrib>Tabata, Sumie</creatorcontrib><creatorcontrib>Yanagita, Soshi</creatorcontrib><creatorcontrib>Matsushita, Akiko</creatorcontrib><creatorcontrib>Ishikawa, Takayuki</creatorcontrib><creatorcontrib>Imai, Hiroyuki</creatorcontrib><creatorcontrib>Takahashi, Takayuki</creatorcontrib><title>Therapeutic Effects of Lenalidomide on Hemorrhagic Intestinal Myeloma-associated AL Amyloidosis</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>A 74-year-old woman with refractory IgG-κ multiple myeloma developed massive melena caused by hemorrhagic submucosal tumors in the duodenum and middle jejunum. A biopsy revealed the tumor to be marked AL amyloid deposition. Treatment with bortezomib did not improve the melena or the underlying disease. The patient also developed multiple amyloidomas in the bilateral femoral heads, which caused a fracture in the left femoral head. Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma. This case shows that successful treatment of multiple myeloma leads to marked improvement of accompanying AL amyloidosis.</description><subject>Aged</subject><subject>AL amyloidosis</subject><subject>Amyloid - metabolism</subject><subject>Amyloidosis - drug therapy</subject><subject>Amyloidosis - etiology</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Blood Transfusion</subject><subject>bone amyloidosis</subject><subject>Bone Diseases - drug therapy</subject><subject>Bone Diseases - etiology</subject><subject>Boronic Acids - administration & dosage</subject><subject>Bortezomib</subject><subject>Carpal Tunnel Syndrome - etiology</subject><subject>Dexamethasone - administration & dosage</subject><subject>Disease Progression</subject><subject>Doxorubicin - administration & dosage</subject><subject>Duodenal Diseases - drug therapy</subject><subject>Duodenal Diseases - etiology</subject><subject>Female</subject><subject>Femur Head - pathology</subject><subject>Fractures, Spontaneous - etiology</subject><subject>Gastrointestinal Hemorrhage - etiology</subject><subject>Gastrointestinal Hemorrhage - therapy</subject><subject>Hip Fractures - etiology</subject><subject>Humans</subject><subject>intestinal amyloidosis</subject><subject>Jejunal Diseases - drug therapy</subject><subject>Jejunal Diseases - etiology</subject><subject>Lenalidomide</subject><subject>Melphalan - administration & dosage</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - complications</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Osteolysis - etiology</subject><subject>Prednisolone - administration & dosage</subject><subject>Pyrazines - administration & dosage</subject><subject>Thalidomide - administration & dosage</subject><subject>Thalidomide - analogs & derivatives</subject><subject>Thalidomide - therapeutic use</subject><subject>Vincristine - administration & dosage</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtPwzAQhC0EglL4C8hHLinxOzlWiJdUxAXO1tbZUKMkLnZ66L_HqKUHhMRlffA3M6sdQigrZ5zp-sYPI8YBuh4b7_yAM8VnlWbqiEyYkHVhuFDHZFLWrCp4HmfkPKWPshSVqfkpOeNCG63qakLs6wojrHEzekfv2hbdmGho6QKzvW9C7xukYaCP2IcYV_CesaecnkafAfq8xS70UEBKwXkYsaHzBZ332y5kcfLpgpy00CW83L9T8nZ_93r7WCxeHp5u54vCaWbGQiqtpVKyAsdBMeAGoAIQIGplZKsaYIov28YIDoyhlK7US4OmUUZrhFZMyfXOdx3D5yavZ3ufHHYdDBg2yTIlZMWYkuJ_VChRiprlI05JtUNdDClFbO06-h7i1rLSfjdhfzdhFbffTWTp1T5ls8yfB-HP6TPwsgM-0gjveAAg5io6_NM5p-a5jziQbgXR4iC-AI-Yp8k</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Nagano, Seiji</creator><creator>Mori, Minako</creator><creator>Kato, Aiko</creator><creator>Ono, Yuichiro</creator><creator>Aoki, Kazunari</creator><creator>Arima, Hiroshi</creator><creator>Takiuchi, Yoko</creator><creator>Tabata, Sumie</creator><creator>Yanagita, Soshi</creator><creator>Matsushita, Akiko</creator><creator>Ishikawa, Takayuki</creator><creator>Imai, Hiroyuki</creator><creator>Takahashi, Takayuki</creator><general>The Japanese Society of Internal Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20130101</creationdate><title>Therapeutic Effects of Lenalidomide on Hemorrhagic Intestinal Myeloma-associated AL Amyloidosis</title><author>Nagano, Seiji ; Mori, Minako ; Kato, Aiko ; Ono, Yuichiro ; Aoki, Kazunari ; Arima, Hiroshi ; Takiuchi, Yoko ; Tabata, Sumie ; Yanagita, Soshi ; Matsushita, Akiko ; Ishikawa, Takayuki ; Imai, Hiroyuki ; Takahashi, Takayuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c617t-456645548ac2a51a27aa8aa3a39574f5da152bfd732a11e44c06b7e7d5766eaf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>AL amyloidosis</topic><topic>Amyloid - metabolism</topic><topic>Amyloidosis - drug therapy</topic><topic>Amyloidosis - etiology</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Blood Transfusion</topic><topic>bone amyloidosis</topic><topic>Bone Diseases - drug therapy</topic><topic>Bone Diseases - etiology</topic><topic>Boronic Acids - administration & dosage</topic><topic>Bortezomib</topic><topic>Carpal Tunnel Syndrome - etiology</topic><topic>Dexamethasone - administration & dosage</topic><topic>Disease Progression</topic><topic>Doxorubicin - administration & dosage</topic><topic>Duodenal Diseases - drug therapy</topic><topic>Duodenal Diseases - etiology</topic><topic>Female</topic><topic>Femur Head - pathology</topic><topic>Fractures, Spontaneous - etiology</topic><topic>Gastrointestinal Hemorrhage - etiology</topic><topic>Gastrointestinal Hemorrhage - therapy</topic><topic>Hip Fractures - etiology</topic><topic>Humans</topic><topic>intestinal amyloidosis</topic><topic>Jejunal Diseases - drug therapy</topic><topic>Jejunal Diseases - etiology</topic><topic>Lenalidomide</topic><topic>Melphalan - administration & dosage</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - complications</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Osteolysis - etiology</topic><topic>Prednisolone - administration & dosage</topic><topic>Pyrazines - administration & dosage</topic><topic>Thalidomide - administration & dosage</topic><topic>Thalidomide - analogs & derivatives</topic><topic>Thalidomide - therapeutic use</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nagano, Seiji</creatorcontrib><creatorcontrib>Mori, Minako</creatorcontrib><creatorcontrib>Kato, Aiko</creatorcontrib><creatorcontrib>Ono, Yuichiro</creatorcontrib><creatorcontrib>Aoki, Kazunari</creatorcontrib><creatorcontrib>Arima, Hiroshi</creatorcontrib><creatorcontrib>Takiuchi, Yoko</creatorcontrib><creatorcontrib>Tabata, Sumie</creatorcontrib><creatorcontrib>Yanagita, Soshi</creatorcontrib><creatorcontrib>Matsushita, Akiko</creatorcontrib><creatorcontrib>Ishikawa, Takayuki</creatorcontrib><creatorcontrib>Imai, Hiroyuki</creatorcontrib><creatorcontrib>Takahashi, Takayuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nagano, Seiji</au><au>Mori, Minako</au><au>Kato, Aiko</au><au>Ono, Yuichiro</au><au>Aoki, Kazunari</au><au>Arima, Hiroshi</au><au>Takiuchi, Yoko</au><au>Tabata, Sumie</au><au>Yanagita, Soshi</au><au>Matsushita, Akiko</au><au>Ishikawa, Takayuki</au><au>Imai, Hiroyuki</au><au>Takahashi, Takayuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic Effects of Lenalidomide on Hemorrhagic Intestinal Myeloma-associated AL Amyloidosis</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>52</volume><issue>10</issue><spage>1101</spage><epage>1105</epage><pages>1101-1105</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>A 74-year-old woman with refractory IgG-κ multiple myeloma developed massive melena caused by hemorrhagic submucosal tumors in the duodenum and middle jejunum. A biopsy revealed the tumor to be marked AL amyloid deposition. Treatment with bortezomib did not improve the melena or the underlying disease. The patient also developed multiple amyloidomas in the bilateral femoral heads, which caused a fracture in the left femoral head. Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma. This case shows that successful treatment of multiple myeloma leads to marked improvement of accompanying AL amyloidosis.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>23676598</pmid><doi>10.2169/internalmedicine.52.8615</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2013, Vol.52(10), pp.1101-1105 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1534811543 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese |
| subjects | Aged AL amyloidosis Amyloid - metabolism Amyloidosis - drug therapy Amyloidosis - etiology Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Blood Transfusion bone amyloidosis Bone Diseases - drug therapy Bone Diseases - etiology Boronic Acids - administration & dosage Bortezomib Carpal Tunnel Syndrome - etiology Dexamethasone - administration & dosage Disease Progression Doxorubicin - administration & dosage Duodenal Diseases - drug therapy Duodenal Diseases - etiology Female Femur Head - pathology Fractures, Spontaneous - etiology Gastrointestinal Hemorrhage - etiology Gastrointestinal Hemorrhage - therapy Hip Fractures - etiology Humans intestinal amyloidosis Jejunal Diseases - drug therapy Jejunal Diseases - etiology Lenalidomide Melphalan - administration & dosage multiple myeloma Multiple Myeloma - complications Multiple Myeloma - drug therapy Osteolysis - etiology Prednisolone - administration & dosage Pyrazines - administration & dosage Thalidomide - administration & dosage Thalidomide - analogs & derivatives Thalidomide - therapeutic use Vincristine - administration & dosage |
| title | Therapeutic Effects of Lenalidomide on Hemorrhagic Intestinal Myeloma-associated AL Amyloidosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T08%3A48%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20Effects%20of%20Lenalidomide%20on%20Hemorrhagic%20Intestinal%20Myeloma-associated%20AL%20Amyloidosis&rft.jtitle=Internal%20Medicine&rft.au=Nagano,%20Seiji&rft.date=2013-01-01&rft.volume=52&rft.issue=10&rft.spage=1101&rft.epage=1105&rft.pages=1101-1105&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.52.8615&rft_dat=%3Cproquest_cross%3E1534811543%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1353039172&rft_id=info:pmid/23676598&rfr_iscdi=true |